Review: Preclinical studies on placenta-derived cells and amniotic membrane: An update

Parolini, Ornella; Caruso, Maddalena

doi:10.1016/j.placenta.2010.12.016

Cited by 87 publications

(72 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parolini's group well reviewed and analyzed regenerative potential of placentaderived cells [74]. Moreover, they demonstrated the effect of human amniotic membrane fragments on restoration of cardiac ischemia (in a rat model), showing an amelioration of cardiac dysfunction [75,76]. These effects may be due to release of mediators rather than direct differentiation of amniotic cells.…”

Section: Human Umbilical Cord: the Hidden Po-tential Of A Discarded Tmentioning

confidence: 99%

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Corrao¹,

Rocca²,

Iacono³

et al. 2013

CSCR

View full text Add to dashboard Cite

Cardiomyopathies are still the first cause of death in the world. The identification of resident stem cells, comprising those derived from sub-endocardial stroma, suggests the possible self regeneration of the heart under autocrine/paracrine modulation in the cardiac microenvironment. Nevertheless, because of the limited in vivo regeneration potential of damaged cardiac tissue, the use of drugs and ultimately cardiac transplantation remain the common treatments of heart diseases and defects. The differentiative potential of embryonic and mesenchymal stem cells (MSCs) derived from different tissues (such as bone marrow and adipose tissue) was extensively explored in cell therapy for regenerative medicine. Many groups have been focused, in recent years, on isolation, characterization, and differentiation potential of MSCs derived from perinatal (or extraembryonic) tissues, mainly the placenta and the human umbilical cord. In this review, we summarized recent works about the stemness of Wharton's jelly stromal cells and their potential in cardiac regeneration with favourable use in cell therapy and regenerative medicine. The peculiar features of these cells, as the expression of cardiac-specific transcription factors and immunomodulatory molecules suggest that human umbilical cord may be considered as a reliable alternative source of MSC useful for advanced therapy in cardiac regenerative medicine.

show abstract

Section: Human Umbilical Cord: the Hidden Po-tential Of A Discarded Tmentioning

confidence: 99%

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Corrao¹,

Rocca²,

Iacono³

et al. 2013

CSCR

View full text Add to dashboard Cite

show abstract

“…This natural membrane presents anti-adhesive, anti-microbial, and anti-inflammatory properties, wound protection and ability to induce epithelialization and pain reduction [24,25]. The invention describes a biological-based method to create a product for regenerating articular cartilage and spinal intervertebral discs prepared with ground or minced placental membranes.…”

Section: Cell Sources and Delivery Methods For Osteochondral Repairmentioning

confidence: 99%

Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what’s new?

López‐Ruiz

Jiménez

García

et al. 2016

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Promising tissue engineering based procedures have emerged as a therapeutic option for the treatment of osteochondral lesions. The development of multilayer scaffolds and the controlled release of bioactive molecules to promote in situ regeneration of both cartilage and bone are some of the latest technologies that intended to improve on the available traditional treatments. To confirm the potential of these novel approaches, long-term evaluation is necessary with special focus on studying the biological and mechanical proprieties of the synthesized tissues.

show abstract

“…성체줄기세포 는 이미 분화된 신체조직에서 추출할 수 있기 때문에 배아의 파괴라는 윤리적인 비판을 피할 수 있고 특히 자기세포를 이 용하는 자가치료의 경우에는 면역 거부반응을 해결할 수 있 다. 특히 태반유래 줄기세포(Placenta-derived stem cell, PDSC) 는 성체줄기세포의 일종으로 태반이라는 특수한 조직에서 유 래한 덕분에 분화 또는 증식능력이 뛰어나 다른 종류의 성체 줄기세포보다 더욱 강력한 세포치료 효과를 가진다 [13,14].…”

Section: 서 론unclassified

Comparison of MicroRNA Expression in Placenta-derived Mesenchymal Stem Cells and Bone Marrow-derived Stem Cells

Kim¹

2014

Journal of Life Science

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have been widely used as cellular therapeutic agents. They have their own characteristic stemness, and thus, they can be used in the treatment of many chronic diseases and in anticancer therapy. MSC therapy has many advantages over chemical therapy. MSC therapy is based on self or homogeneous origin; as such, it is expected to be effective in the treatment of various diseases. In addition, microRNAs in particular have been studied for their structure and function, and they are also expected to prove effective for use as therapeutic agents in cancer or chronic diseases. MicroRNAs are largely associated with metabolism and homeostasis. Therefore, over-or under-expression of microRNAs leads to chronic diseases. Conversely, effective control of the expression of specific microRNAs reduces the risk of many chronic diseases. However, there have been no reports thus far on the synergistic effects of MSCs and microRNAs. Therefore, in this study, we examined the relationship between MSCs and microRNAs using placenta-derived MSCs (PDSCs), bone marrow-derived MSCs (BM-MSCs), and fibroblast (WI-38) cells. We studied the expression of some microRNAs in MSCs and compared the expression in each cell line and cell passage. As a result, we found that the expression of microRNA-34a was higher in PDSCs than in BM-MSCs and that the expression of microRNA-27a, 33a, 33b, and 211 was higher in BM-MSCs than in PDSCs. Therefore, we expect that each MSC line will be used as cell therapy, considering its expressed functional microRNA.

show abstract

Review: Preclinical studies on placenta-derived cells and amniotic membrane: An update

Cited by 87 publications

References 43 publications

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Polymers, scaffolds and bioactive molecules with therapeutic properties in osteochondral pathologies: what’s new?

Comparison of MicroRNA Expression in Placenta-derived Mesenchymal Stem Cells and Bone Marrow-derived Stem Cells

Contact Info

Product

Resources

About